文献速递关节外科运动医学

曲安奈德对人类健康与骨关节炎膝关节软骨无直接损害

Triamcinolone Acetonide Is Not Harmful to Healthy and Osteoarthritic Human Knee Cartilage.
PubMed 文献 · Am J Sports Med · 2026-04-21

本研究在体外条件下,将人类健康与骨关节炎(OA)软骨暴露于曲安奈德(TA)200 μM或1 nM,评估软骨细胞活力和基质代谢。结果显示TA未降低软骨细胞活力,未增加基线GAG丢失,仅在远超临床暴露的浓度下轻度、可逆地抑制基质合成。结论支持TA用于滑膜炎管理时对软骨完整性直接风险极小。

要点

  • TA不降低健康或OA人类软骨的软骨细胞活力,不增加基线GAG丢失。
  • 持续14天200 μM TA使OA软骨GAG合成降低26%、健康软骨降低18%,1 nM无影响。
  • 单次注射模拟(2天暴露+14天恢复)对健康软骨GAG或胶原合成无影响。

核心结论

  • 在完整人类软骨的体外实验条件下,TA对软骨细胞无毒性,仅在远超临床暴露的剂量下轻度、可逆地抑制基质合成。
  • 关节内TA用于滑膜炎管理时,对软骨完整性的直接风险极小。

研究设计与样本

  • 对照实验室研究。
  • 人类软骨取自尸体供体膝关节(平均年龄38岁;4例男性)或全膝关节置换残余(平均年龄66岁;9例女性、7例男性)。
  • 样本暴露于TA 200 μM(0.087 mg/mL)或1 nM,评估软骨细胞活力和基因表达,并用点击化学法量化GAG和胶原合成及GAG丢失。
  • 测试两种给药方案:连续14天暴露(模拟多次注射)和2天暴露后14天恢复(模拟单次注射)。

主要发现

  • TA未降低软骨细胞活力,未增加软骨样本的基线GAG丢失。
  • 健康软骨中,TA下调MMP13(均值±标准差:1.0 ± 0.8 vs 0.4 ± 0.2;P = .04)和COL2A1(1.0 ± 0.3 vs 0.5 ± 0.2;P = .003)。
  • OA软骨中,200 μM TA下调MMP13(1.0 ± 0.7 vs 0.2 ± 0.3;P = .02)、ADAMTS5(1.0 ± 0.3 vs 0.4 ± 0.1;P = .03)和COL2A1(1.0 ± 0.3 vs 0.7 ± 0.2;P = .05)。
  • 连续14天200 μM TA使OA软骨GAG合成降低26%(P < .001)、健康软骨降低18%(P = .004),1 nM TA无影响。
  • 胶原合成仅在健康软骨中降低:200 μM TA降低25%(P < .001),1 nM TA降低21%(P = .004)。

关键数值与推荐

  • TA浓度:200 μM(0.087 mg/mL)和1 nM。
  • 连续14天200 μM TA使OA软骨GAG合成降低26%(P < .001),健康软骨降低18%(P = .004)。
  • 健康软骨胶原合成降低25%(200 μM TA;P < .001)和21%(1 nM TA;P = .004)。

临床怎么用

  • 支持关节内TA用于滑膜炎管理,缓解对直接软骨损伤的担忧,即使多次注射。
  • 注意体外实验中高浓度TA(200 μM)对基质合成有轻度可逆抑制,但该浓度远超临床暴露。

局限性

  • 体外研究,不能完全反映体内关节环境。
  • 样本来自尸体供体或全膝关节置换残余,可能不代表所有患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-articular triamcinolone acetonide (TA) injections are commonly used to manage joint synovitis despite reports that they accelerate cartilage degeneration. Previous studies found that TA minimally affected bovine cartilage, but effects in human cartilage remain unclear. PURPOSE: To determine how TA in physiologically relevant concentrations influences chondrocyte viability and matrix metabolism in healthy and osteoarthritic (OA) human cartilage. STUDY DESIGN: Controlled laboratory study. METHODS: Human cartilage was harvested from cadaver donor knees (mean age, 38 years; 4 male) or total knee replacement remnants (mean age, 66 years; 9 female, 7 male). Samples were exposed to TA, 200 μM (0.087 mg/mL) or 1 nM, to evaluate chondrocyte viability and gene expression. A high-resolution click chemistry assay quantified glycosaminoglycan (GAG) and collagen synthesis and tracked GAG loss. Two dosing regimens were tested: a continuous 14-day exposure (multiple-injection simulation) and a 2-day exposure followed by a 14-day recovery (single-injection simulation). RESULTS: TA did not reduce chondrocyte viability and did not increase baseline GAG loss from the cartilage samples. In healthy cartilage, TA downregulated MMP13 (mean ± SD; 1.0 ± 0.8 vs 0.4 ± 0.2; P = .04) and COL2A1 (1.0 ± 0.3 vs 0.5 ± 0.2; P = .003). In OA cartilage, 200 μM TA downregulated MMP13 (1.0 ± 0.7 vs 0.2 ± 0.3; P = .02), ADAMTS5 (1.0 ± 0.3 vs 0.4 ± 0.1; P = .03), and COL2A1 (1.0 ± 0.3 vs 0.7 ± 0.2; P = .05). A continuous 14-day 200 μM TA exposure reduced GAG synthesis by 26% in OA cartilage (P < .001) and 18% in healthy cartilage (P = .004), but 1 nM TA had no effect. Collagen synthesis was reduced only in healthy cartilage by 25% (200 μM TA; P < .001) and 21% (1 nM TA; P = .004). A single-injection simulation produced no change in GAG or collagen synthesis in healthy cartilage. CONCLUSION: In intact human cartilage under these experimental conditions, TA had no measurable toxicity to chondrocytes and only modestly, reversibly suppressed matrix synthesis at doses far exceeding clinical exposure. Intra-articular TA poses minimal measured direct risk to cartilage integrity when used for synovitis management. CLINICAL RELEVANCE: These findings support the clinical use of TA for synovitis while alleviating concerns about direct cartilage damage, even with multiple injections.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Porter A, Nguyen J, Peng Y, et al. Triamcinolone Acetonide Is Not Harmful to Healthy and Osteoarthritic Human Knee Cartilage. Am J Sports Med. 2026. PMID: 42011976. doi:10.1177/03635465261439028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。